CN107410785B - 一种可快速补充体能的人参皂苷饮料 - Google Patents
一种可快速补充体能的人参皂苷饮料 Download PDFInfo
- Publication number
- CN107410785B CN107410785B CN201710689630.8A CN201710689630A CN107410785B CN 107410785 B CN107410785 B CN 107410785B CN 201710689630 A CN201710689630 A CN 201710689630A CN 107410785 B CN107410785 B CN 107410785B
- Authority
- CN
- China
- Prior art keywords
- ginsenoside
- physical performance
- beverage
- saponins
- rapidly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229930182494 ginsenoside Natural products 0.000 title claims abstract description 44
- 229940089161 ginsenoside Drugs 0.000 title claims abstract description 41
- 230000001502 supplementing effect Effects 0.000 title claims abstract description 21
- 235000013361 beverage Nutrition 0.000 title claims abstract description 19
- 230000036314 physical performance Effects 0.000 title claims abstract description 17
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 33
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 22
- 229930182490 saponin Natural products 0.000 claims abstract description 21
- 150000007949 saponins Chemical class 0.000 claims abstract description 21
- 235000017709 saponins Nutrition 0.000 claims abstract description 21
- 239000002994 raw material Substances 0.000 claims abstract description 13
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 11
- 229930006000 Sucrose Natural products 0.000 claims abstract description 11
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 11
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 11
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 11
- 235000015203 fruit juice Nutrition 0.000 claims abstract description 11
- 239000000178 monomer Substances 0.000 claims abstract description 11
- 239000008213 purified water Substances 0.000 claims abstract description 11
- 239000011780 sodium chloride Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 241000628997 Flos Species 0.000 claims description 9
- 239000005720 sucrose Substances 0.000 claims description 9
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 2
- 229960004793 sucrose Drugs 0.000 abstract description 9
- 235000020510 functional beverage Nutrition 0.000 abstract description 5
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 229960002668 sodium chloride Drugs 0.000 abstract description 3
- 235000007516 Chrysanthemum Nutrition 0.000 abstract description 2
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract description 2
- 235000015165 citric acid Nutrition 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 235000002639 sodium chloride Nutrition 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 235000003140 Panax quinquefolius Nutrition 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 241000208340 Araliaceae Species 0.000 description 7
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 7
- 235000008434 ginseng Nutrition 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 229920002527 Glycogen Polymers 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 230000009182 swimming Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000006820 DNA synthesis Effects 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 240000005373 Panax quinquefolius Species 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000004565 tumor cell growth Effects 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 230000000703 anti-shock Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- CNHRRMQBWQJRPN-UHFFFAOYSA-N chikusetsusaponin LM5 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C1O CNHRRMQBWQJRPN-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- JDCPEKQWFDWQLI-LUQKBWBOSA-N ginsenoside Rc Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O JDCPEKQWFDWQLI-LUQKBWBOSA-N 0.000 description 1
- SPFXZQZPHXUJSR-UHFFFAOYSA-N ginsenoside-Rc Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1OC2OC(CO)C(O)C2O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C SPFXZQZPHXUJSR-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 150000003431 steroids Chemical group 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
本发明公开了一种可快速补充体能的人参皂苷饮料,包括以下原料:人参皂苷、果汁、柠檬酸、菊花、氯化钠、蔗糖、抗坏血酸、其余为纯净水,在传统的功能饮料的基础上添加了人参皂苷,并对不同的单体皂苷的协同作用作了深入的研究,最终确定了可以快速补充体能的四类单体皂苷:Rg2、Rh、Rb3和Ro;并辅以其它单体皂苷,最终得到的功能饮料,补充体能效果好,无副作用。
Description
技术领域
本发明涉及运动型功能饮料技术领域,尤其涉及一种可快速补充体能的人参皂苷饮料。
背景技术
从美国到世界各地,一般大众对草药的热衷及另类医疗的成长,使得有非常多针对人参皂苷的研究。在美国,人参年销售额超过3亿美元,而占有草药市场的15%至20%,所以人参是美国消费者最常用的中草药之一。
在美国,人参制剂被列为饮食补充剂;但在欧洲,尤其是德国人则把人参当作药品。在几个欧洲国家,人参及其他草药被医生当作处方签,植物医药原理也再次在医学院中被讲授。在设定医疗性草药安全及疗效的E委员会专刊中,德国政府认可人参可作为疲劳和乏力时的补品。
国内对人参总皂苷提取的比较多,但提取人参皂苷单体的较少,因为技术难度比较高,目前国内具备生产人参皂苷单体条件的企业极少,如果是购买单体产品一般建议查看该产品说明书上标注的是人参总皂苷或是单体皂苷。
根据研究皂苷成分具有如下作用:
Rh2:具有抑制癌细胞向其它器官转移,增强机体免疫力,快速恢复体质的作用。对癌细胞具有明显的抗转移作用,可配合手术服用增强手术后伤口的愈合及体力的恢复。人体吸收率在16%,最高含量在16.2%。
Rg:具有兴奋中枢神经,抗疲劳、改善记忆与学习能力、促进DNA、RNA合成的作用。
Rg1:可快速缓解疲劳、改善学习记忆、延缓衰老,具有兴奋中枢神经作用、抑制血小板凝集作用。
Rg2:具有抗休克作用,快速改善心肌缺血和缺氧,治疗和预防冠心病。
Rg3:可作用于细胞生殖周期的G2期,抑制癌细胞有丝分裂前期蛋白质和ATP的合成,使癌细胞的增殖生长速度减慢,并且具有抑制癌细胞浸润、抗肿瘤细胞转移、促进肿瘤细胞凋亡、抑制肿瘤细胞生长等作用。
Rg5:抑制癌细胞浸润、抗肿瘤细胞转移、促进肿瘤细胞凋亡、抑制肿瘤细胞生长
Rb1:西洋参(花旗参)的含量最多,具影响动物睾丸的潜力,亦会影响小鼠的胚胎发育,具有增强胆碱系统的功能,增加乙酰胆碱的合成和释放以及改善记忆力作用。
Rb2:DNA,RNA的合成促进作用、脑中枢调节具有抑制中枢神经,降低细胞内钙,抗氧化,清除体内自由基和改善心肌缺血再灌注损伤等作用。
Rc:人参皂甙-Rc是一种人参中的固醇类分子。具有抑制癌细胞的功能。可增加精虫的活动力。
Rb3:可增强心肌功能,保护人体自身免疫系统。可以用于治疗各种不同原因引起的心肌收缩性衰竭。
Rh:具有抑制中枢神经、催眠作用,镇痛、安神、解热、促进血清蛋白质合成作用。
Rh1:具有促进肝细胞增殖和促进DNA合成的作用,可用于治疗和预防肝炎、肝硬化。
Ro:具有消炎、解毒、抗血栓作用,抑制酸系血小板凝结以及抗肝炎作用活化巨噬细胞作用。
为了进一步提高人参皂苷的经济价值,有必要研究一种可快速补充体能的人参皂苷饮料。
发明内容
基于背景技术存在的技术问题,本发明提出了一种可快速补充体能的人参皂苷饮料。
本发明的技术方案如下:
一种可快速补充体能的人参皂苷饮料,包括以下原料:人参皂苷、果汁、柠檬酸、菊花、氯化钠、蔗糖、抗坏血酸、其余为纯净水。
一种可快速补充体能的人参皂苷饮料,包括以下重量百分比的原料:人参皂苷0.005-0.05%、果汁10-15%、柠檬酸0.02-0.05%、菊花1-3%、氯化钠0.05-0.1%、蔗糖0.5-0.8%、抗坏血酸0.001-0.005%、其余为纯净水。
优选的,所述的人参皂苷,包含以下种类的单体皂苷:Rg2、Rh、Rb3和Ro。
进一步优选的,所述的人参皂苷,还包括以下种类的单体皂苷中的一种或者多种的组合:Rg1、Rg、Rb2和Rh1。
本发明的可快速补充体能的人参皂苷饮料,包括以下原料:人参皂苷、果汁、柠檬酸、菊花、氯化钠、蔗糖、抗坏血酸、其余为纯净水,在传统的功能饮料的基础上添加了人参皂苷,并对不同的单体皂苷的协同作用作了深入的研究,最终确定了可以快速补充体能的四类单体皂苷:Rg2、Rh、Rb3和Ro;并辅以其它单体皂苷,最终得到的功能饮料,补充体能效果好,无副作用。
具体实施方式
实施例1:
一种可快速补充体能的人参皂苷饮料,包括以下重量百分比的原料:人参皂苷0.02%、果汁12%、柠檬酸0.03%、菊花2.5%、氯化钠0.08%、蔗糖0.7%、抗坏血酸0.003%、其余为纯净水。
所述的人参皂苷,包含以下种类的单体皂苷:Rg2、Rh、Rb3、Ro、Rg1和Rh1。
实施例2:
一种可快速补充体能的人参皂苷饮料,包括以下重量百分比的原料:人参皂苷0.005%、果汁15%、柠檬酸0.02%、菊花3%、氯化钠0.05%、蔗糖0.8%、抗坏血酸0.001%、其余为纯净水。
所述的人参皂苷,包含以下种类的单体皂苷:Rg2、Rh、Rb3、Ro、Rg1、Rg、Rb2和Rh1。
实施例3:
一种可快速补充体能的人参皂苷饮料,包括以下重量百分比的原料:人参皂苷0.05%、果汁10%、柠檬酸0.05%、菊花1%、氯化钠0.1%、蔗糖0.5%、抗坏血酸0.005%、其余为纯净水。
所述的人参皂苷,包含以下种类的单体皂苷:Rg2、Rh、Rb3、Ro。Rg1、Rg和Rb2。
实施例4:
一种可快速补充体能的人参皂苷饮料,包括以下重量百分比的原料:人参皂苷0.008%、果汁10%、柠檬酸0.03%、菊花1.5%、氯化钠0.05%、蔗糖0.8%、抗坏血酸0.004%、其余为纯净水。
所述的人参皂苷,包含以下种类的单体皂苷:Rg2、Rh、Rb3、Ro、Rg、Rb2和Rh1。
实施例5:
一种可快速补充体能的人参皂苷饮料,包括以下重量百分比的原料:人参皂苷0.035%、果汁12.5%、柠檬酸0.04%、菊花2%、氯化钠0.08%、蔗糖0.55%、抗坏血酸0.002%、其余为纯净水。
所述的人参皂苷,包含以下种类的单体皂苷:Rg2、Rh、Rb3、Ro和Rh1。
以下将实施例1中的各原料的百分比含量固定,对不同种类的单体皂苷的协同作用进行具体的分析:
表1:不同对比例中的单体皂苷的的含量:
原料百分比 | Rg2 | Rh | Rb3 | Ro | Rg1 | Rg | Rb2 | Rh1 |
实施例1 | 30 | 20 | 15 | 20 | 5 | 0 | 0 | 10 |
对比例1 | 0 | 35 | 25 | 40 | 0 | 0 | 0 | 0 |
对比例2 | 50 | 0 | 25 | 25 | 0 | 0 | 0 | 0 |
对比例3 | 40 | 35 | 0 | 25 | 0 | 0 | 0 | 0 |
对比例4 | 40 | 30 | 30 | 0 | 0 | 0 | 0 | 0 |
对比例5 | 30 | 15 | 10 | 20 | 15 | 10 | 0 | 0 |
对比例6 | 30 | 15 | 10 | 20 | 10 | 0 | 15 | 0 |
对比例7 | 30 | 15 | 10 | 20 | 10 | 0 | 0 | 15 |
对比例8 | 30 | 15 | 10 | 20 | 0 | 10 | 15 | 0 |
对比例9 | 30 | 15 | 10 | 20 | 0 | 0 | 10 | 15 |
对比例10 | 30 | 15 | 10 | 20 | 10 | 5 | 5 | 5 |
下面对实施例1以及对比实施例1-10的饮料进行小鼠灌胃测试,具体测试方法如下:将120只小鼠按体重随机分成12组:空白对照组、实施例1和对比实施例1-10,每组10只,用北京维通利华实验动物技术有限公司提供的标准饲料分笼饲养,自由饮食饮水。适应性喂养5天后进行灌胃试验。
每日分别给实验组小鼠灌胃,小鼠定时测定体重,根据体重计算灌胃的量,灌胃量为:25ml/日/kg,连续灌胃30天。
连续灌胃30天,末次灌胃1小时后,各组小鼠测试负重游泳时间;各组小鼠禁食16小时(过夜),然后1次性灌胃给予50%乙醇12ml/kg体重,6小时后取材(空白对照组不作处理,不禁食取材),测试尿素氮含量和肝糖原含量。
结果表明,各组小鼠体重的增长差异不大,动物在试验过程中活动正常,无异常表现,表明饮料对小鼠的生长发育和健康无不良影响。具体负重游泳时间、尿素氮含量和肝糖原含量测试结果如下:
表2:不同对比例中的小鼠负重游泳时间、尿素氮含量和肝糖原含量测试结果:
由以上测试数据可以知道,本发明的可快速补充体能的人参皂苷饮料中,各种单体皂苷具有协同作用。
以上所述,仅为本发明较佳的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,根据本发明的技术方案及其发明构思加以等同替换或改变,都应涵盖在本发明的保护范围之内。
Claims (2)
1.一种可快速补充体能的人参皂苷饮料,其特征在于,包括以下重量百分比的原料:人参皂苷0.005-0.05%、果汁10-15%、柠檬酸0.02-0.05%、菊花1-3%、氯化钠0.05-0.1%、蔗糖0.5-0.8%、抗坏血酸0.001-0.005%、其余为纯净水;
所述的人参皂苷,包含以下种类的单体皂苷:Rg2、Rh、Rb3和Ro;
所述的人参皂苷,还包括以下种类的单体皂苷中的至少两种:Rg1、Rg、Rb2和Rh1。
2.如权利要求1所述的可快速补充体能的人参皂苷饮料,其特征在于,包括以下重量百分比的原料:人参皂苷0.02%、果汁12%、柠檬酸0.03%、菊花2.5%、氯化钠0.08%、蔗糖0.7%、抗坏血酸0.003%、其余为纯净水;所述的人参皂苷,包含以下重量百分比的单体皂苷:Rg2 30%、Rh 20%、Rb3 15%、Ro 20%、Rg1 5%和Rh1 10%。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710689630.8A CN107410785B (zh) | 2017-08-14 | 2017-08-14 | 一种可快速补充体能的人参皂苷饮料 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710689630.8A CN107410785B (zh) | 2017-08-14 | 2017-08-14 | 一种可快速补充体能的人参皂苷饮料 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107410785A CN107410785A (zh) | 2017-12-01 |
CN107410785B true CN107410785B (zh) | 2020-11-03 |
Family
ID=60437957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710689630.8A Active CN107410785B (zh) | 2017-08-14 | 2017-08-14 | 一种可快速补充体能的人参皂苷饮料 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107410785B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102228494A (zh) * | 2011-05-10 | 2011-11-02 | 北京采瑞医药科技有限公司 | 一种扶正固本、增强人体免疫力、抗疲劳、抗肿瘤、延缓衰老的中药组合物 |
CN106360349A (zh) * | 2016-10-09 | 2017-02-01 | 李志军 | 一种糙米和藜麦混合营养粥的制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59118053A (ja) * | 1982-12-24 | 1984-07-07 | Hayashibara Biochem Lab Inc | 飲食物とその製造方法 |
KR20100025303A (ko) * | 2008-08-27 | 2010-03-09 | 씨제이제일제당 (주) | 인삼 사포닌의 기능이 강화된 기능성 음료 조성물 |
CN101756090B (zh) * | 2009-12-18 | 2012-08-01 | 中国人民武装警察部队后勤学院 | 体力恢复剂及用途 |
CN102687821A (zh) * | 2012-05-04 | 2012-09-26 | 长春中医药大学 | 人参总皂苷为添加剂的系列运动功能饮料的制备方法 |
CN104222234B (zh) * | 2014-09-22 | 2018-07-27 | 熊慧 | 一种含有人参和阿胶的组合物 |
CN104839846A (zh) * | 2015-05-08 | 2015-08-19 | 吉林大学 | 一种人参功能保健运动饮料及其制备方法 |
-
2017
- 2017-08-14 CN CN201710689630.8A patent/CN107410785B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102228494A (zh) * | 2011-05-10 | 2011-11-02 | 北京采瑞医药科技有限公司 | 一种扶正固本、增强人体免疫力、抗疲劳、抗肿瘤、延缓衰老的中药组合物 |
CN106360349A (zh) * | 2016-10-09 | 2017-02-01 | 李志军 | 一种糙米和藜麦混合营养粥的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN107410785A (zh) | 2017-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3560507B1 (en) | Traditional chinese medicine combination for regulating immune function and preparation method therefor | |
US7371416B2 (en) | Method for preparing processed ginseng to obtain increased amount of ginsenoside RG5 | |
CN109010618B (zh) | 一种具有抗肿瘤作用的中药组合物及制备方法和应用 | |
KR20100127420A (ko) | 사포닌의 생체 이용률 증진 조성물 | |
CN107050148A (zh) | 一种解酒保肝中药组合物及其制备方法 | |
KR100770775B1 (ko) | 면역증강을 위한 기능성 음료 및 그 제조방법 | |
CN108014150B (zh) | 天然药物组合物在制备抗缺氧和抗辐射的药物或食品中的应用 | |
TWI569803B (zh) | 靈芝多醣體用於抑制脂肪肝形成之用途及其製備方法 | |
CN104997883A (zh) | 一种桦褐孔菌树莓刺莓组合物、桦褐孔菌树莓刺莓复合口服液及其制备方法和应用 | |
KR101052574B1 (ko) | 인삼으로부터 진세노사이드 Rg1 또는 Rb1이 강화된 추출물 분획을 제조하는 방법 | |
CN107006856A (zh) | 一种增强耐力、提高抗缺氧耐受力营养剂及其制备方法 | |
CN105796861A (zh) | 连翘苷、连翘苷衍生物、连翘苷与连翘脂素组合物在制备提高免疫功能的药物中的应用 | |
CN107412254B (zh) | 金线莲多糖提取物的应用 | |
Liu et al. | Polysaccharides derived from natural edible and medicinal sources as agents targeting exercise-induced fatigue: A review | |
CN107410785B (zh) | 一种可快速补充体能的人参皂苷饮料 | |
KR101435930B1 (ko) | 진세노사이드 Rg3 강화 홍삼 추출물제조방법 및 그 제조방법 의한 진세노사이드 Rg3 강화 홍삼 추출물을 유효성분으로 함유하는 제품 | |
KR101336094B1 (ko) | 피부 개선용 건강기능식품 조성물 및 그 제조방법 | |
CN109122856A (zh) | 一种护肝醒酒中药组合物 | |
CN108576346A (zh) | 一种能抗癌降压降糖降血脂的桦褐孔菌压片糖果 | |
CN103705561A (zh) | 一种洋参果药用组合物及制备方法和用途 | |
CN104523851A (zh) | 一种水红花子果皮总黄酮提取物的制备方法 | |
KR101058422B1 (ko) | 한방 건강 보조 식품 및 그의 제조방법 | |
CN1255037C (zh) | 一种营养茶及其制备方法 | |
CN112137088A (zh) | 一种具有抗氧化、延缓衰老功效的复方组合物及其制备方法与应用 | |
US10383904B2 (en) | Composition for improving health and quality of life of women containing ginseng berry extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20200930 Address after: 130000 No. 2476 liberty Road, Nanguan District, Jilin, Changchun Applicant after: JILIN INSTITUTE OF PHYSICAL EDUCATION Address before: 130000 Linhe street, Changchun economic and Technological Development Zone, Jilin, 5699 Applicant before: Liu Zhier |
|
GR01 | Patent grant | ||
GR01 | Patent grant |